R-pharm
Clinical trials sponsored by R-pharm, explained in plain language.
-
New melanoma drug aims to match Keytruda's success
Disease control CompletedThis phase 3 trial compares a new drug, RPH-075, to the established immunotherapy Keytruda (both are forms of pembrolizumab) in people with advanced or spreading skin melanoma that cannot be surgically removed. The study aims to see if RPH-075 is as effective as Keytruda at shrin…
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a cheaper copy of keytruda work just as well against cancer?
Disease control CompletedThis study tests whether a new drug called RPH-075, a biosimilar of pembrolizumab (Keytruda), works as well as the original in people with skin melanoma, lung cancer, or head and neck cancer. Participants receive a single dose of either RPH-075 or Keytruda, and researchers compar…
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New biosimilar RPH-002 takes on erbitux in head and neck cancer showdown
Disease control CompletedThis phase 3 trial compares a new drug, RPH-002, to the standard treatment Erbitux in 161 patients with advanced head and neck cancer that cannot be removed by surgery. Both drugs are given with chemotherapy. The main goal is to see if RPH-002 works as well as Erbitux in shrinkin…
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New biosimilar RPH-002 takes on erbitux in head and neck cancer trial
Disease control CompletedThis Phase 1 trial compared a new biosimilar drug, RPH-002, to the standard cancer drug Erbitux in 118 patients with advanced head and neck cancer that could not be removed by surgery. The main goals were to see if RPH-002 reaches similar levels in the blood and has a similar saf…
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC